Columbus Circle Investors decreased its position in Agilent Technologies, Inc. (NYSE:A) by 74.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,231 shares of the medical research company’s stock after selling 94,979 shares during the period. Columbus Circle Investors’ holdings in Agilent Technologies were worth $1,912,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in the company. Wetherby Asset Management Inc. increased its position in shares of Agilent Technologies by 9.3% in the first quarter. Wetherby Asset Management Inc. now owns 6,027 shares of the medical research company’s stock worth $319,000 after buying an additional 512 shares during the period. Wesbanco Bank Inc. acquired a new position in shares of Agilent Technologies during the first quarter worth about $215,000. Whittier Trust Co. increased its position in shares of Agilent Technologies by 1.3% in the first quarter. Whittier Trust Co. now owns 14,401 shares of the medical research company’s stock worth $762,000 after buying an additional 182 shares during the period. AMF Pensionsforsakring AB acquired a new position in shares of Agilent Technologies during the first quarter worth about $17,911,000. Finally, Shell Asset Management Co. increased its position in shares of Agilent Technologies by 20.4% in the first quarter. Shell Asset Management Co. now owns 60,747 shares of the medical research company’s stock worth $3,212,000 after buying an additional 10,299 shares during the period.
Agilent Technologies, Inc. (A) opened at 62.68 on Friday. The firm has a 50-day moving average price of $60.63 and a 200 day moving average price of $56.52. Agilent Technologies, Inc. has a 52-week low of $42.92 and a 52-week high of $63.37. The stock has a market cap of $20.18 billion, a PE ratio of 32.33 and a beta of 1.30.
Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.07. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company earned $0.49 EPS. Equities analysts anticipate that Agilent Technologies, Inc. will post $2.32 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Columbus Circle Investors Has $1.91 Million Stake in Agilent Technologies, Inc. (A)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://stocknewstimes.com/2017/08/25/columbus-circle-investors-has-1-91-million-stake-in-agilent-technologies-inc-a.html.
A has been the subject of a number of research analyst reports. Robert W. Baird upped their price target on Agilent Technologies from $57.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, May 24th. Jefferies Group LLC reissued a “buy” rating and issued a $66.00 price objective on shares of Agilent Technologies in a report on Wednesday, August 9th. Morgan Stanley increased their price objective on Agilent Technologies from $65.00 to $70.00 and gave the company an “overweight” rating in a report on Wednesday, May 24th. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Finally, Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 price objective for the company in a report on Tuesday, May 16th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $63.18.
In other news, insider Patrick Kaltenbach sold 5,000 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $63.26, for a total value of $316,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Didier Hirsch sold 72,545 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $62.38, for a total value of $4,525,357.10. The disclosure for this sale can be found here. In the last three months, insiders sold 146,233 shares of company stock worth $9,015,016.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
